[Management of patients with essential thrombocythemia]

Med Clin (Barc). 2013 Mar 16;140(6):278-82. doi: 10.1016/j.medcli.2012.10.007. Epub 2012 Nov 21.
[Article in Spanish]
No abstract available

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Bone Marrow / pathology
  • Cytostatic Agents / adverse effects
  • Cytostatic Agents / therapeutic use*
  • Disease Management
  • Female
  • Genetic Predisposition to Disease
  • Hemorrhage / chemically induced
  • Humans
  • Interferon-alpha / adverse effects
  • Interferon-alpha / therapeutic use
  • Janus Kinase 2 / genetics
  • Lactation
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Point Mutation
  • Pregnancy
  • Pregnancy Complications, Hematologic / drug therapy
  • Quinazolines / therapeutic use
  • Thrombocythemia, Essential / classification
  • Thrombocythemia, Essential / diagnosis
  • Thrombocythemia, Essential / drug therapy*
  • Thrombocythemia, Essential / epidemiology
  • Thrombocythemia, Essential / pathology
  • Thrombophilia / drug therapy
  • Thrombophilia / etiology

Substances

  • Cytostatic Agents
  • Interferon-alpha
  • Platelet Aggregation Inhibitors
  • Quinazolines
  • JAK2 protein, human
  • Janus Kinase 2
  • anagrelide